NOVARTIS AG-REG (NOT.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:NOT - CH0012005267 - Common Stock
NOT.DE Key Statistics, Chart & Performance
The current stock price of NOT.DE is 119.74 EUR. In the past month the price increased by 5.09%.
NOT.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| SAN.PA | SANOFI | 10.89 | 201.00B | ||
| SNW.DE | SANOFI | 10.83 | 199.86B | ||
| 1SAN.MI | SANOFI | 10.69 | 197.40B | ||
| MRK.DE | MERCK KGAA | 14.93 | 55.37B | ||
| UCB.BR | UCB SA | 39.89 | 49.81B | ||
| UNC.DE | UCB SA | 38.68 | 48.30B | ||
| 1BAYN.MI | BAYER AG-REG | 7.12 | 37.38B | ||
| BAYN.DE | BAYER AG-REG | 7.18 | 37.67B | ||
| IPN.PA | IPSEN | 11.85 | 10.20B | ||
| TUB.BR | FINANCIERE DE TUBIZE | 108.89 | 10.08B | ||
| REC.MI | RECORDATI INDUSTRIA CHIMICA | 24.5 | 10.09B | ||
| 1JAZZ.MI | JAZZ PHARMACEUTICALS PLC | 21.2 | 8.94B |
Related stock screener links
About NOT.DE
Company Profile
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 75,883 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Company Info
NOVARTIS AG-REG
Lichtstrasse 35
Basel BASEL-STADT CH
Employees: 75883
Phone: 41613241111
NOVARTIS AG-REG / NOT.DE FAQ
Can you describe the business of NOVARTIS AG-REG?
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 75,883 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
What is the stock price of NOVARTIS AG-REG today?
The current stock price of NOT.DE is 119.74 EUR. The price increased by 2.18% in the last trading session.
Does NOT stock pay dividends?
NOVARTIS AG-REG (NOT.DE) has a dividend yield of 3.19%. The yearly dividend amount is currently 3.23.
What is the ChartMill technical and fundamental rating of NOT stock?
NOT.DE has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the Price/Earnings (PE) ratio of NOVARTIS AG-REG (NOT.DE)?
The PE ratio for NOVARTIS AG-REG (NOT.DE) is 15.76. This is based on the reported non-GAAP earnings per share of 7.6 and the current share price of 119.74 EUR.
What is the next earnings date for NOT stock?
NOVARTIS AG-REG (NOT.DE) will report earnings on 2026-02-04, after the market close.
NOT.DE Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to NOT.DE.
NOT.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to NOT.DE. NOT.DE has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
NOT.DE Financial Highlights
Over the last trailing twelve months NOT.DE reported a non-GAAP Earnings per Share(EPS) of 7.6. The EPS increased by 21.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 25.69% | ||
| ROA | 13.42% | ||
| ROE | 32.47% | ||
| Debt/Equity | 0.55 |
NOT.DE Forecast & Estimates
31 analysts have analysed NOT.DE and the average price target is 116.52 EUR. This implies a price decrease of -2.69% is expected in the next year compared to the current price of 119.74.
For the next year, analysts expect an EPS growth of 16.78% and a revenue growth 9.91% for NOT.DE